Poolbeg Pharma’s new drug could be used to treat flu – and possibly Covid too

Poolbeg Pharma

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables them to develop multiple products faster and more cost effectively than the traditional biotech model.

Poolbeg aspires to become a “one-stop shop” for big pharma to find Phase II ready products for development and commercialisation.

The company has access to a unique private repository of clinical samples and associated data from human challenge trials. This resource is anticipated to expand over coming years. Human challenge trial data is unique in the depth of longitudinal virology, health, biomarker and symptom data collected during the course of disease.

This weekend the Daily Mail wrote an article on Poolbeg and gave them a BUY reccomendation.

You can read the full article here:

https://www.dailymail.co.uk/money/investing/article-9914439/MIDAS-SHARE-TIPS-Poolbeg-Pharma-prove-exciting-opportunity.html

You might also enjoy reading  Poolbeg Pharma to present at investor conferences
Find more news, interviews, share price & company profile here for:
Poolbeg Pharma plc

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit
Find more news, interviews, share price & company profile here for:
Poolbeg Pharma plc

AIM All Share Index